151. ESC Working Group Cellular Biology of the Heart: Position Paper: improving the preclinical assessment of novel cardioprotective therapies
- Author
-
Derek M. Yellon, Michel Ovize, Péter Ferdinandy, Derek J. Hausenloy, Rosalinda Madonna, Linda W. van Laake, Felix B. Engel, Hans Erik Bøtker, David Garcia-Dorado, Rainer Schulz, Marisol Ruiz-Meana, Gerd Heusch, Gianluigi Condorelli, Sandrine Lecour, Sean M. Davidson, Joost P.G. Sluijter, Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Institut National de la Recherche Agronomique (INRA), Institut National de la Recherche Agronomique (INRA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), and Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Subjects
Myocardial ischemia ,Physiology ,[SDV]Life Sciences [q-bio] ,Treatment outcome ,Medizin ,Myocardial Ischemia ,Heart position ,Cardioprotection ,030204 cardiovascular system & hematology ,Ischaemia ,03 medical and health sciences ,0302 clinical medicine ,Medizinische Fakultät ,Physiology (medical) ,medicine ,Animals ,Myocardial infarction ,ddc:610 ,Translational Medical Research ,030304 developmental biology ,Cause of death ,0303 health sciences ,business.industry ,Animal ,Animal models ,Reperfusion ,Disease Models, Animal ,Evaluation Studies as Topic ,Experimental Animal Models ,medicine.disease ,3. Good health ,Cell biology ,Disease Models ,Topical Reviews ,Position paper ,Ischaemic heart disease ,Cardiology and Cardiovascular Medicine ,business - Abstract
International audience; Ischaemic heart disease (IHD) remains the leading cause of death and disability worldwide. As a result, novel therapies are still needed to protect the heart from the detrimental effects of acute ischaemia-reperfusion injury, in order to improve clinical outcomes in IHD patients. In this regard, although a large number of novel cardioprotective therapies discovered in the research laboratory have been investigated in the clinical setting, only a few of these have been demonstrated to improve clinical outcomes. One potential reason for this lack of success may have been the failure to thoroughly assess the cardioprotective efficacy of these novel therapies in suitably designed preclinical experimental animal models. Therefore, the aim of this Position Paper by the European Society of Cardiology Working Group Cellular Biology of the Heart is to provide recommendations for improving the preclinical assessment of novel cardioprotective therapies discovered in the research laboratory, with the aim of increasing the likelihood of success in translating these new treatments into improved clinical outcomes.
- Published
- 2014